Keytruda Price Per Dose vs. Per Year — Full Breakdown (2025)
2025-09-24
•
92 views
Keytruda (pembrolizumab) is one of the most widely prescribed immunotherapy drugs for cancer, but its cost continues to be a major concern for patients in 2025. On average, a single 200 mg intravenous dose is estimated at around $11,700 under Medicare ASP pricing, while a 6-week 400 mg dose carries a published list price of $23,590. Depending on the treatment plan, annual costs can exceed $200,000 per patient. In 2025, Merck also introduced a new subcutaneous formulation (Keytruda QLEX), which offers shorter administration times but could bring different pricing models compared to IV dosing. Insurance coverage, Medicare billing rules, and patient assistance programs remain critical factors in determining real out-of-pocket costs.
Read More
